Damsky W, et al. - Since Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling plays a role in sarcoidosis pathogenesis, researchers treated a patient with cutaneous sarcoidosis with the JAK inhibitor tofacitinib. Study participants included the patient who had not previously had a response to medications and had not received systemic glucocorticoids. Findings suggested that sequencing of RNA and immunohistochemical examination of skin-lesion samples obtained from the patient prior to and during therapy and immunohistochemical testing of lesion samples obtained from other patients with cutaneous sarcoidosis play a role in the signaling of JAK-STAT in cutaneous sarcoidosis.